Monday, December 23, 2024
HomeTagsPhase 1/2 EXPLORE44

Phase 1/2 EXPLORE44

Avidity Biosciences Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates announced the Phase 1/2 EXPLORE44™...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics